Skip to main content
. 2014 Dec 30;26(3):326–333. doi: 10.1111/nmo.12264

Figure 3.

Figure 3

Percentages of patients with specified improvements in abdominal pain at week 12 (pooled IBS-C phase 3 ITT population). At week 12, a greater percentage of patients treated with linaclotide met incremental levels of improvement in abdominal pain compared with placebo patients (p < 0.0001 for linaclotide compared with placebo for each percent level of improvement using Fisher's exact test).